Compass Rose Archives

Idea to Investment Podcast: How FACIT’s support propels early cancer innovations

Posted on January 17, 2025 (January 27, 2025) by Ricky

January 17, 2025 – FACIT’s David Koehler, Director of Fund Operations, appeared on TechAlliance’s Idea to Investment podcast along with Saumik Biswas, President, CEO and Founder of Tenomix Inc. based in London, Ontario. Tenomix’s advancements exemplifies how FACIT’s continuum of commercialization programs can strategically capitalize on homegrown talent and innovations to spur promising start-ups to grow roots in Ontario and bring cancer solutions to benefit patients sooner.

Esphera SynBio closes seed financing round to advance their lead designer cancer vaccine

Posted on January 7, 2025 (March 6, 2025) by Ricky

January 7, 2025 – FACIT congratulates portfolio company, Esphera SynBio (“Esphera”), on successfully securing seed financing and strategic partners to continue developing bespoke cancer immunotherapies using their proprietary engineered exosome-based platform for improved vaccine efficacy.

FACIT investment in cTRL Therapeutics focuses cell therapy R&D on Ontario for patients with cancer

Posted on October 10, 2024 (March 6, 2025) by Ricky

October 10, 2024 – cTRL Therapeutics announced it is strengthening its research and development operations in Canada. Following an investment by FACIT, the company will establish a state-of-the-art laboratory and leverage Ontario’s world-leading cancer research network to accelerate advancement of its cancer therapeutics pipeline to benefit patients sooner.

Radiant Biotherapeutics reaches milestone to advance its new class of therapeutics against complex cancers

Posted on September 11, 2024 (December 12, 2024) by Ricky

September 11, 2024 – FACIT seeded start-up, Radiant Biotherapeutics (“Radiant”), announced the closing of Series A financing to advance the company’s proprietary multi-specific therapeutics for patients with complex cancers. Radiant’s unique multi-valent antibody platform, called Multabody™, generates best-in-class antibodies with superior potency against multiple target sites implicated in heterogenous diseases such as cancers and can potentially improve patient outcome.

FACIT portfolio company HDAX Therapeutics closes seed financing to target CNS cancers and neuropathies

Posted on September 5, 2024 (December 12, 2024) by Ricky

September 5, 2024 – FACIT congratulates HDAX Therapeutics (“HDAX”) on the closing of a seed financing round to develop their best-in-class HDAC therapeutics for the treatment of a serious cancer conditions. Capital from the investor group, which included an investment from FACIT’s Compass Rose Oncology Fund, will empower HDAX to address the debilitating neuropathic pain frequently experienced by patients with cancer.

FACIT leads seed round in Nanology Labs

Posted on May 18, 2021 (July 4, 2024) by jeremy

May 18, 2021 – May 18, 2021 – FACIT deploys Ontario First capital, enables rising local start-up to reach critical value inflection point. FACIT has previously supported Nanology, spun out of the University of Toronto, through both its early-stage Prospects Oncology Fund and seed-stage Compass Rose Oncology Fund.

FACIT announces follow-on investments in Xpan Inc. and Nanology Labs through Compass Rose Fund

Posted on January 28, 2020 (July 4, 2024) by jeremy

January 28, 2020 – January 28, 2020 – Spun out of the University of Toronto, both start-ups have previously received funding through FACIT’s proof-of-concept Prospects Fund.